Ocugen's most advanced product candidate, OCU400, has started Phase 3 clinical trials, aiming for regulatory approval in the U.S. and Europe by 2026. The gene therapy platform shows promise in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback